Intrinsa aftershocks?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioSante will meet with FDA in the first quarter to discuss the status of its female sexual dysfunction product LibiGel, the firm said upon announcement of P&G's withdrawal of its FSD patch Intrinsa. BioSante is planning to begin Phase III trials of its testosterone gel. Other firms have been counting on Intrinsa to pave the way for their FSD submissions (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24)...